Form 8-K LEXICON PHARMACEUTICALS, For: Feb 05
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 8-K
__________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 30, 2015
Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 000-30111 | 76-0474169 |
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) |
8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of principal executive
offices and Zip Code)
(281) 863-3000
(Registrants telephone number,
including area code)
Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17�CFR�230.425) |
o | Soliciting material pursuant to Rule 14a12 under the Exchange Act (17�CFR 240.14a12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17�CFR 240.14d2(b)) |
o | Pre-commencement communications pursuant to Rule 13e4(c) under the Exchange Act (17�CFR�240.13e4(c)) |
Item 1.02 | Termination of a Material Definitive Agreement |
On January 30, 2015, Griffin Partners, Inc. ( Griffin Partners ) terminated the Real Estate Purchase and Sale Agreement, dated November 14, 2014, between Griffin Partners and our wholly-owned subsidiary Lex-Gen Woodlands, L.P. (the Agreement ) due to uncertainty in real estate and financing market conditions.
Under the Agreement, we had agreed to sell our facilities in The Woodlands, Texas (the Property ) to Griffin Partners for a purchase price of $24.5 million. Such sale was subject to normal and customary closing conditions, including a study period, which extended until February 2, 2015, during which Griffin Partners could conduct inspections, analyses and other studies of the Property and was permitted to terminate the Agreement in its discretion.
We intend to explore other strategic alternatives with respect to the Property consistent with our strategy to reduce facilities costs, including the potential sale of the Property to an alternative third party.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lexicon Pharmaceuticals, Inc. | ||
Date: February 5, 2015 | By: | /s/ Brian T. Crum |
Brian T. Crum | ||
Vice�President and General Counsel | ||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LINCOLN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Lincoln National Corporation and Encourages Investors to Contact the Firm
- ADSK INVESTOR ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Autodesk, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADSK
- CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
